Such effects may contribute to the therapeutic effect or be detrimental to ocular tissue in neovascular diseases, as has been observed in case of anti-VEGF therapeutics in AMD models and clinical settings49–51. This evidence concerns the gene VEGFA and age-related macular degeneration.